Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

New Opportunities in Advanced KRAS Mutation-Positive NSCLC

Access Activity

Overview / Abstract:

In this CME/NCPD activity, D. Ross Camidge, MD, PhD, of the University of Colorado, and Beth Sandy, MSN, CRNP, OCN®, of the University of Pennsylvania, discuss novel treatments for advanced KRAS mutation-positive NSCLC and how to manage adverse events associated with small molecule inhibitors. Start now! 

An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 84% of cases are classified as non-small cell. Most patients are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management (ACS, 2020). Although 70% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop progressive disease within 5 months of their final cycle (Lazzari et al, 2017). Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine selection of novel therapies has improved outcomes for some patients. Unfortunately, the 5-year survival rate for patients with NSCLC remains a dismal 24%, indicating a need for continued research on more effective approaches to tumor control (ACS, 2020; NCI, 2019).


Upon completion of this activity, participants should be able to:

Discuss the therapeutic implications of KRAS G12 mutation status in advanced NSCLC
Assess emerging data on novel small molecule inhibitors for advanced KRAS mutation–positive NSCLC
Apply strategies to manage adverse events associated with novel small molecular inhibitors for advanced KRAS mutation-positive NSCLC


Mar 25, 2022


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Podcast, Webinar / Webcast / Video

Credits / Hours

0.75 CME | 0.75 NCPD | MOC | ILNA



Presenters / Authors / Faculty

D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado

Beth Sandy, MSN, CRNP, OCN®
Nurse Practitioner
University of Pennsylvania

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Amgen.

Keywords / Search Terms

i3 Health i3 Health i3 Health i3 Health, NSCLC, non-small cell lung cancer, KRAS Mutation–Positive NSCLC, NSCLC online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME Free CE CME Free CE CME Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map